Alkem Laboratories Ltd has informed to the exchanges that US FDA had conducted an inspection of the Company’s manufacturing facility located at St. Louis,
As per the regulatory filing, at the end of the inspection, the Company has received Form 483 with three observations. The Company shall submit to US FDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection, said Alkem.
On Monday early morning trade, Alkem Laboratories was trading at Rs3055.55 per share lower by 1.36% on the BSE.
